QWO
Peakcollagenase clostridium histolyticum-aaes
BLASUBCUTANEOUSSOLUTION
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QWO is a subcutaneous collagenase solution approved in 2020 for cellulite treatment in adults. It is an injectable biologic that enzymatically degrades collagen in the dermal septae responsible for cellulite dimpling. The product represents a novel mechanism for non-invasive cosmetic dermatology.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30%); commercial teams are likely focused on market penetration and durability rather than growth scaling.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QWO offers limited publicly linked job openings (0 at time of analysis), but roles exist primarily in commercial execution, dermatology field sales, and account management within specialty aesthetic medicine. Career growth is tied to market expansion success in a niche cosmetic indication with stable but not hypergrowth commercial trajectory.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.